A meta-analysis of 30 trials found GLP-1 drugs lower systolic blood pressure by about 3.4 mmHg in overweight patients, regardless of diabetes status or which specific drug is used.
-3.37 mmHg systolic BPGLP-1 receptor agonists lowered systolic blood pressure by an average of 3.37 mmHg across 30 trials and 37,072 patients — a clinically meaningful population-level reduction
What the researchers found
Across 30 randomized controlled trials involving 37,072 patients, GLP-1 receptor agonists reduced systolic blood pressure by an average of 3.37 mmHg (95% CI -3.95 to -2.80) and diastolic blood pressure by 1.05 mmHg (95% CI -1.46 to -0.65) compared to placebo in overweight or obese patients.
The blood pressure lowering effect was consistent regardless of whether patients had diabetes, which GLP-1 drug formulation was used, how long treatment lasted, or whether the drug was injected or taken orally — with the exception of exenatide. Meta-regression found no significant correlation between blood pressure reduction and baseline age, sex, HbA1c, weight, BMI, or existing hypertension status.
Why it matters
High blood pressure is the leading modifiable risk factor for heart disease and stroke, and it's extremely common in overweight and obese patients. This meta-analysis provides the strongest evidence to date that GLP-1 drugs — already prescribed for diabetes and weight loss — also meaningfully lower blood pressure. A ~3.4 mmHg systolic reduction at the population level translates into significant cardiovascular risk reduction, adding another benefit to an already compelling drug class.
The numbers in context
30 RCTs · n=37,072 · SBP -3.37 mmHg (95% CI -3.95 to -2.80) · DBP -1.05 mmHg (95% CI -1.46 to -0.65) · consistent across diabetic status and drug formulations
How the study worked
Systematic review and meta-analysis of randomized controlled trials identified from PubMed, EMBASE, and CENTRAL databases (inception to February 2024). Pair-wise meta-analysis with random effects models, fixed effects meta-analysis to unify treatment effects across GLP-1 RA doses, and random effects meta-regression to explore correlations between blood pressure reduction and baseline patient characteristics.
Who was studied
Overweight or obese adults (with and without type 2 diabetes) from 30 randomized controlled trials
What this study cannot tell us
Individual patient data was not available, limiting subgroup analyses. The blood pressure reductions, while statistically significant, are modest in absolute terms. The exception of exenatide from the consistent class effect warrants further investigation. Studies varied in follow-up duration and specific GLP-1 RA used, introducing some heterogeneity.
How to read the evidence
Rated high because this is a well-conducted meta-analysis of 30 randomized controlled trials with over 37,000 patients, systematic search of multiple databases, and robust statistical methods including meta-regression.
When this study was published
Published in 2025 with literature through February 2024, this is among the most comprehensive and current meta-analyses on GLP-1 drugs and blood pressure.
The bigger picture
GLP-1 receptor agonists continue to reveal benefits beyond their original diabetes indication. With weight loss, cardiovascular protection, and now confirmed blood pressure reduction, these drugs are emerging as comprehensive metabolic therapies. For the millions of overweight patients with hypertension, a single drug that addresses multiple risk factors simultaneously could simplify treatment and improve outcomes.
Questions still open
- Why does exenatide appear to be the exception among GLP-1 drugs for blood pressure reduction?
- Is the blood pressure lowering effect independent of weight loss, or entirely driven by it?
- Could GLP-1 drugs eventually replace or reduce the need for dedicated blood pressure medications in obese patients?
Common questions
How much does a 3.4 mmHg blood pressure drop actually matter?
Do you need to be diabetic for GLP-1 drugs to lower your blood pressure?
Read the original research
Effects of glucagon-like peptide-1 receptor agonists on blood pressure in overweight or obese patients: a meta-analysis of randomized controlled trials.
Journal of hypertension, 43(2), 290-300
Citation
Wong, Hon Jen; Toh, Keith Zhi Xian; Teo, Yao Hao; Teo, Yao Neng; Chan, Mark Y; Yeo, Leonard L L; Eng, Pei Chia; Tan, Benjamin Y Q; Zhou, Xin; Yang, Qing; Dalakoti, Mayank; Sia, Ching-Hui. (2025). Effects of glucagon-like peptide-1 receptor agonists on blood pressure in overweight or obese patients: a meta-analysis of randomized controlled trials.. Journal of hypertension, 43(2), 290-300. https://doi.org/10.1097/HJH.0000000000003903